Linaclotide + Placebo
ApprovedTerminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Irritable Bowel Syndrome Characterized by Constipation
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Trial Timeline
Dec 21, 2016 → Oct 31, 2018
NCT ID
NCT02837783About Linaclotide + Placebo
Linaclotide + Placebo is a approved stage product being developed by Ironwood Pharmaceuticals for Irritable Bowel Syndrome Characterized by Constipation. The current trial status is terminated. This product is registered under clinical trial identifier NCT02837783. Target conditions include Irritable Bowel Syndrome Characterized by Constipation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04110145 | Phase 2 | Completed |
| NCT03573908 | Phase 3 | Completed |
| NCT02837783 | Approved | Terminated |
Competing Products
20 competing products in Irritable Bowel Syndrome Characterized by Constipation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| linaclotide + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| Ramosetron + Placebo | Astellas Pharma | Approved | 85 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| YM060 + placebo | Astellas Pharma | Phase 2 | 52 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| linaclotide + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron | Astellas Pharma | Pre-clinical | 23 |
| YM060 | Astellas Pharma | Phase 2 | 52 |
| ONO-2952 + Placebo comparator | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2952 + ONO-2952 Matching Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| duloxetine | Eli Lilly | Approved | 85 |
| Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers) | AbbVie | Phase 3 | 77 |
| 25mg Eluxadoline + 100mg Eluxadoline | AbbVie | Phase 3 | 77 |
| Eluxadoline + Placebo | AbbVie | Phase 2 | 52 |
| Placebo + Linaclotide | AstraZeneca | Phase 3 | 77 |
| Tegaserod | Novartis | Pre-clinical | 23 |
| DNK333 | Novartis | Phase 2 | 52 |
| SMS995 + Placebo | Novartis | Phase 1 | 33 |